Cargando…

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Millan, Belen, Sanchéz-Martínez, Diego, Roca-Ho, Heleia, Gutiérrez-Agüera, Francisco, Molina, Oscar, Diaz de la Guardia, Rafael, Torres-Ruiz, Raúl, Fuster, Jose Luís, Ballerini, Paola, Suessbier, Ute, Nombela-Arrieta, Cesar, Bueno, Clara, Menéndez, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755967/ https://www.ncbi.nlm.nih.gov/pubmed/30635633 http://dx.doi.org/10.1038/s41375-018-0353-0

Ejemplares similares

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
por: Prieto, C, et al.
Publicado: (2018)

Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
por: Prieto, C., et al.
Publicado: (2018)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions
por: Bueno, Clara, et al.
Publicado: (2019)

The “Never-Ending” Mouse Models for MLL-Rearranged Acute Leukemia Are Still Teaching Us
por: Ottersbach, Katrin, et al.
Publicado: (2018)

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
por: Zangrando, Andrea, et al.
Publicado: (2009)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

Engraftment characterization of risk-stratified AML in NSGS mice
por: Díaz de la Guardia, Rafael, et al.
Publicado: (2021)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells
por: Petazzi, Paolo, et al.
Publicado: (2020)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia
por: Oliveira, Tiago, et al.
Publicado: (2021)

PROM1 and CTGF Expression in Childhood MLL-Rearrangement Acute Lymphoblastic Leukemia
por: Wang, Lu-lu, et al.
Publicado: (2022)

Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia
por: Zhang, Hao, et al.
Publicado: (2020)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
por: Velasco-Hernandez, Talia, et al.
Publicado: (2020)

Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency
por: Muñoz-López, Alvaro, et al.
Publicado: (2016)

Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
por: Roolf, C., et al.
Publicado: (2018)

Identification of hub genes and molecular mechanisms in infant acute lymphoblastic leukemia with MLL gene rearrangement
por: Zhang, Hao, et al.
Publicado: (2019)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Modality Attention and Sampling Enables Deep Learning with Heterogeneous Marker Combinations in Fluorescence Microscopy
por: Gomariz, Alvaro, et al.
Publicado: (2021)

Erratum: Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2016)

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
por: Cruickshank, M N, et al.
Publicado: (2017)

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)

EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age
por: Stevens, A, et al.
Publicado: (2014)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

RNA binding proteins in MLL-rearranged leukemia
por: Tran, Tiffany M., et al.
Publicado: (2022)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia
por: Moschiano, Elizabeth, et al.
Publicado: (2016)

MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
por: Matlawska-Wasowska, Ksenia, et al.
Publicado: (2016)

Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement
por: Wang, Qian, et al.
Publicado: (2017)

PAFc, a Key Player in MLL-rearranged Leukemogenesis
por: Tan, Jiaying, et al.
Publicado: (2010)

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
por: Winters, Amanda C., et al.
Publicado: (2017)

Molecular pathogenesis of disease progression in MLL-rearranged AML
por: Kotani, Shinichi, et al.
Publicado: (2018)

IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML
por: Lopez-Millan, Belen, et al.
Publicado: (2018)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax
por: Fidyt, Klaudyna, et al.
Publicado: (2022)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
por: Lopez-Millan, Belen, et al.
Publicado: (2022)

Initiation of MLL-rearranged AML is dependent on C/EBPα
por: Ohlsson, Ewa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9bp5rnc4j4corn2meelp1trbbr